Essential Partners’s Edgewise Therapeutics EWTX Stock Holding History

Essential Partners’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$122	Hold	3	–	–	﹤0.01%	2723
2026 Q1	$95	Hold	3	–	–	﹤0.01%	2722
2025 Q4	$74	Buy	+3	New	+$60	﹤0.01%	2593

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Essential Partners's EWTX Position: Q2 2026 in Review

Essential Partners held its Edgewise Therapeutics (EWTX) position steady in Q2 2026 at 3 shares worth $122. The position accounts for ﹤0.01% of the portfolio, ranked #2723.

Essential Partners first reported a position in EWTX in Q4 2025 and has held it in 3 quarters since. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

Essential Partners held 3 shares of Edgewise Therapeutics worth $122 as of Q2 2026.
Essential Partners left its Edgewise Therapeutics share count unchanged in Q2 2026.
Edgewise Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2723 holding.
Essential Partners first reported a position in Edgewise Therapeutics in Q4 2025 and has held it in 3 quarters since.
225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.